Interventions for Tuberculosis Control and Elimination 2002

606. Crofton J, Chaulet P, Maher D, Grosset J, Harris W, Horne N, Iseman M, Watt B.
Guidelines for the management of drug-resistant tuberculosis.
Health Organization 1996; 96.210(Rev. 1): 1-40.
Geneva: World
607. World Health Organization. Coordination of DOTS-plus pilot projects for the
management of MDR-TB.
1-16.
WHO/CDS/CDC/TB/99.262: Geneva: WHO, 1999;
608. World Health Organization. Guidelines for establishing DOTS-Plus projects for
the managment of multidrug-resistant tuberculosis (MDR-TB).
2000.279: Geneva: WHO, 2000; 1-87.
WHO/CDS/TB/
609. World Health Organization. Report. Multidrug resistant tuberculosis (MDR TB).
Basis for the development of an evidence-based case-management strategy for
MDR TB within the WHO’s DOTS strategy.
1999.
WHO/TB/99.260: Geneva: WHO,
610. Farmer P, Kim JY. Community based approaches to the control of multidrug
resistant tuberculosis: introducing “DOTS-plus”. BMJ 1998; 317: 671-4.
611. Farmer P, Furin J, Bayona J, Becerra M, Henry C, Hiatt H, Kim JY, Mitnick C,
Nardell E, Shin S. Management of MDR-TB in resource-poor countries.
(Counter counterpoint). Int J Tuberc Lung Dis 1999; 3: 643-5.
612. Van Deun A, Hamid Salim A, Rigouts L, Rahman M, Fissette K, Portaels F.
Evaluation of tuberculosis control by periodic or routine susceptibility testing in
previously treated cases. Int J Tuberc Lung Dis 2001; 5: 329-38.
613. Murray CJL, De Jonghe E, Chum HJ, Nyangulu DS, Salomao A, Styblo K. Cost
effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan
African countries. Lancet 1991; 338: 1305-8.
614. Chum HJ, Ilmolelian G, Rieder HL, Msangi J, Mwinyi N, Zwahlen M,
Enarson DA, Ipuge YA. Impact of the change from an injectable to a fully oral
regimen on patient adherence to ambulatory treatment in Dar es Salaam, Tanzania.
Tubercle Lung Dis 1995; 76: 286-9.
615. Boisier P, Rabarijaona L, Rakotomanana F, Ratsitorahina M, Ratsirahonana O, Roux
J, Aurégan G. Comparaison de protocoles thérapeutiques utilisés en routine à
Madagascar dans le traitement des tuberculoses pulmonaires à microscopie positive.
(Résultats préliminaires). Arch Inst Pasteur Madagascar 1995; 62: 72-6.
616. Gninafon M, Lambregts-van Weezenbeek CSB, Tawo L, Trebucq A. Ethambutol
versus streptomycin during the hospitalized intensive phase of tuberculosis treatment
in Benin. (Correspondence). Tubercle Lung Dis 1995; 76: 373-4.
617. Singapore Tuberculosis Service, British Medical Research Council. Clinical trial
of three 6-month regimens of chemotherapy given intermittently in the continuation
phase in the treatment of pulmonary tuberculosis.
132: 374-8.
Am Rev Respir Dis 1985;
618. Okwera A, Whalen C, Byekwaso F, Vjecha M, Johnson J, Huebner R, Mugerwa R,
Ellner J. Randomised trial of thiacetazone and rifampicin-containing regimens for
pulmonary tuberculosis in HIV-infected Ugandans. Lancet 1994; 344: 1323-8.
210